Drug intelligence / Profile preview

ABX-PTH

Development stage: Preclinical
Lead developer: Amgen
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics

Overview

ABX-PTH is a fully human monoclonal antibody developed by Abgenix. It is designed to target and neutralize parathyroid hormone (PTH), thereby acting as a PTH antagonist. The drug was investigated for its potential use in treating secondary hyperparathyroidism, chronic renal failure, and other parathyroid disorders. While it was explored for therapeutic applications, no clinical trials or regulatory approvals have been identified, suggesting its development as a pharmaceutical product may have been discontinued or not progressed to market. Research-grade biosimilar versions of Anti-Parathyroid Hormone Antibody [ABX-PTH] are available for scientific study.

Other names: Anti-Parathyroid Hormone Antibody [ABX-PTH]

Beyond the preview

Go deeper on ABX-PTH.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ABX-PTH.

Explore the full profile